Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors.

NCT06177405 is registered in ClinicalTrials.gov with Institute of Biomedical Chemistry, Russia as lead sponsor.

NCT NCT06177405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06177405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors.
Lead sponsor
Institute of Biomedical Chemistry, Russia
Phase
Observational
Overall status
Completed
Start date
January 15, 2021
Completion date
November 1, 2023
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis